KR20040003200A - Galenical extract inhibiting Helicobacter pyroli urease activity and their use - Google Patents
Galenical extract inhibiting Helicobacter pyroli urease activity and their use Download PDFInfo
- Publication number
- KR20040003200A KR20040003200A KR1020020037836A KR20020037836A KR20040003200A KR 20040003200 A KR20040003200 A KR 20040003200A KR 1020020037836 A KR1020020037836 A KR 1020020037836A KR 20020037836 A KR20020037836 A KR 20020037836A KR 20040003200 A KR20040003200 A KR 20040003200A
- Authority
- KR
- South Korea
- Prior art keywords
- distilled water
- herbal extract
- helicobacter pylori
- extract
- column chromatography
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 47
- 108010046334 Urease Proteins 0.000 title claims description 46
- 230000002401 inhibitory effect Effects 0.000 title claims description 44
- 230000000694 effects Effects 0.000 title claims description 23
- 241000589989 Helicobacter Species 0.000 title description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 45
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 33
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000012153 distilled water Substances 0.000 claims abstract description 29
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 244000269722 Thea sinensis Species 0.000 claims abstract description 15
- 235000015140 cultured milk Nutrition 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract 4
- 239000012676 herbal extract Substances 0.000 claims description 37
- 238000004440 column chromatography Methods 0.000 claims description 26
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 235000009569 green tea Nutrition 0.000 claims description 13
- 238000005119 centrifugation Methods 0.000 claims description 11
- 238000005194 fractionation Methods 0.000 claims description 9
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 9
- 235000013527 bean curd Nutrition 0.000 claims description 7
- 235000013361 beverage Nutrition 0.000 claims description 7
- 238000000638 solvent extraction Methods 0.000 claims description 5
- 239000002601 urease inhibitor Substances 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 239000000401 methanolic extract Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000469 ethanolic extract Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 244000241872 Lycium chinense Species 0.000 abstract description 10
- 102000057297 Pepsin A Human genes 0.000 abstract description 10
- 108090000284 Pepsin A Proteins 0.000 abstract description 10
- 229940111202 pepsin Drugs 0.000 abstract description 10
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 8
- 238000000605 extraction Methods 0.000 abstract description 8
- 208000007107 Stomach Ulcer Diseases 0.000 abstract description 5
- 238000010438 heat treatment Methods 0.000 abstract description 5
- 235000008216 herbs Nutrition 0.000 abstract description 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 4
- 235000013399 edible fruits Nutrition 0.000 abstract description 4
- 206010017758 gastric cancer Diseases 0.000 abstract description 4
- 201000005917 gastric ulcer Diseases 0.000 abstract description 4
- 201000011549 stomach cancer Diseases 0.000 abstract description 4
- 241001618264 Rubus coreanus Species 0.000 abstract description 2
- 235000006468 Thea sinensis Nutrition 0.000 abstract description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 235000019985 fermented beverage Nutrition 0.000 abstract description 2
- 244000237330 gutta percha tree Species 0.000 abstract description 2
- 229940093499 ethyl acetate Drugs 0.000 abstract 1
- 235000019439 ethyl acetate Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 10
- 235000015459 Lycium barbarum Nutrition 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 108010059712 Pronase Proteins 0.000 description 7
- 241000411851 herbal medicine Species 0.000 description 7
- 239000013014 purified material Substances 0.000 description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 239000006049 herbal material Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000003811 acetone extraction Methods 0.000 description 4
- 239000011149 active material Substances 0.000 description 4
- 239000012223 aqueous fraction Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 235000020687 goji berry extract Nutrition 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000003808 methanol extraction Methods 0.000 description 3
- 235000021278 navy bean Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960002460 nitroprusside Drugs 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000209507 Camellia Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229940090496 Urease inhibitor Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229910001919 chlorite Inorganic materials 0.000 description 1
- 229910052619 chlorite group Inorganic materials 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000003779 heat-resistant material Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- -1 hydrogen ions Chemical class 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- RSAZYXZUJROYKR-UHFFFAOYSA-N indophenol Chemical compound C1=CC(O)=CC=C1N=C1C=CC(=O)C=C1 RSAZYXZUJROYKR-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 위궤양 및 위암의 원인균으로 알려진 헬리코박터 파이로리(Helicobacter pylori)균의 항균활성을 갖는 복분자, 녹차잎, 두충껍질, 구기자 등의 생약추출물에 관한 것으로서, 보다 구체적으로는 생약 소재인 복분자, 녹차잎, 두충껍질, 구기자 등을 포함하는 군(group)으로부터 선택된 1종 이상의 식물추출액을 함유하며 위궤양 및 위암의 원인균인 헬리코박터 파이로리 우레아제 활성을 억제함으로써 헬리코박터 파이로리에 대하여 항균활성을 갖는 것을 특징으로 하는 생약 추출물 및 그 용도에 관한 것이다.The present invention relates to herbal extracts, such as bokbunja, green tea leaves, tofu peel, wolfberry having antibacterial activity of Helicobacter pylori bacteria known as the causative agent of gastric ulcer and stomach cancer, more specifically bokbunja, green tea leaf Herbal medicine extract, characterized in that it contains antimicrobial activity against Helicobacter pylori by containing one or more plant extracts selected from the group including caterpillar bark, goji berry, etc. and inhibiting Helicobacter pylori urease activity, which is the causative agent of gastric ulcer and stomach cancer And uses thereof.
헬리코박터 파이로리균은 1983년에 호주의 Marshall과 Warren에 의해 발견되었으며, 위염 및 위궤양 환자의 위점막 생검조직으로부터 그람음성의 만곡형 간균으로 관찰되어, B형 만성위염과 위십이지장 궤양을 유발시키며 위암발생의 일차적 결정요인으로 알려져 있다.Helicobacter pylori was discovered in 1983 by Marshall and Warren of Australia and was observed as a Gram-negative curved bacillus from gastric mucosal biopsy tissue of patients with gastritis and gastric ulcer, causing type B chronic gastritis and gastroduodenal ulcer and It is known as the primary determinant of.
헬리코박터 파이로리균은 위산이 분비되는 위점막을 서식처로 삼고 있다. 그러나 강력한 우레아제 생성능을 가지고 있어, 이 우레아제에 의해 인체내의 요소를 암모니아와 이산화탄소로 분해하여 암모니아를 만들어 내고, 생성된 암모니아가 헬리코박터 파이로리 주위의 강산성 위액을 중화시키면서 일종의 보호막을 만들므로써, 강산성의 위에서 생존할 수 있다.Helicobacter pylori is home to the gastric mucosa of the stomach. However, it has a strong ability to produce urease, which causes urease to decompose urea in the body into ammonia and carbon dioxide to produce ammonia. can do.
뿐만 아니라, 헬리코박터 파이로리 우레아제에 의해 생산된 암모니아는 위점막에 축적되어, 직·간접적으로 위점막의 손상을 초래하므로써 위염이나 위십이지장 궤양을 유발시킨다는 가설도 있다.In addition, there is a hypothesis that ammonia produced by Helicobacter pylori urease accumulates in the gastric mucosa, causing gastric mucosal ulcers by directly or indirectly damaging the gastric mucosa.
헬리코박터 파이로리균은 시험관(in vitro)내에서는 각종 항균제에 잘 사멸하는 균이다. 그러나, 생체내에서는 시판 항균제로 이 균을 제거하기 어렵다. 그 이유는 이 세균이 살아가는 서식처가 수소이온 및 여러 화학물질의 침투가 어려운 위점막 상피세포간 접합부와 점액층이기 때문이다.Helicobacter pylori is a bacterium that is killed by various antimicrobial agents in vitro. However, it is difficult to remove these bacteria in vivo with commercially available antibacterial agents. This is because the colony's habitat is the junction and mucous layer between the gastric mucosa epithelial cells where hydrogen ions and various chemicals are difficult to penetrate.
본 발명의 목적은 헬리코박터 파이로리의 생체내의 생존을 억제하기 위해, 헬리코박터 파이로리 생존의 가장 큰 조건이 되는 우레아제의 활성을 저해함으로써 헬리코박터 파이로리의 생육을 억제시키고 우레아제에 의해 생성된 암모니아성 질환을 예방하는 생약추출물 및 그 용도를 제공하는 것이다.It is an object of the present invention to suppress the in vivo survival of Helicobacter pylori, to inhibit the activity of urease, which is the largest condition of Helicobacter pylori survival, to prevent the growth of Helicobacter pylori and prevent ammonia disease produced by urease It is to provide an extract and its use.
도 1은 복분자 조말 추출물의 용매분획 과정을 나타낸 흐름도이다.1 is a flowchart illustrating a solvent fractionation process of bokbunja pome extract.
도 2는 도 1의 과정에서 분획된 복분자 추출물의 각 분획별 우레아제 저해 활성을 측정하여 나타낸 것이다.Figure 2 shows the measured urease inhibitory activity of each fraction of the bokbunja extract fractionated in the process of FIG.
도 3은 복분자추출물(RCW2)로부터 조제된 프로나제소화물과 과옥소산 산화물의 우레아제 저해 활성을 나타낸 것이다.Figure 3 shows the urease inhibitory activity of pronase digestion and peroxo acid oxide prepared from bokbunja extract (RCW2).
도 4는 DEAE-토요펄 650C 컬럼 크로마토그래피에 의해 용출된 각 분획별 우레아제 저해활성을 측정하여 나타낸 것이다.Figure 4 shows the measured urease inhibitory activity of each fraction eluted by DEAE-Toyopearl 650C column chromatography.
도 5는 부틸-토요펄 650M 컬럼 크로마토그래피에 의한 RCW2-Ⅲ의 용출패턴을 나타낸 것이다.Figure 5 shows the elution pattern of RCW2-III by butyl-Toyopearl 650M column chromatography.
도 6은 부틸-토요펄 650M 컬럼 크로마토그래피에 의해 용출된 각 분획별 우레아제 저해 활성을 나타낸 것이다.Figure 6 shows the urease inhibitory activity of each fraction eluted by butyl-Toyopearl 650M column chromatography.
도 7은 세파덱스 LH-20 컬럼 크로마토그래피에 의한 RCW2-Ⅲc의 용출패턴을 나타낸 것이다.Figure 7 shows the elution pattern of RCW2-IIIc by Sephadex LH-20 column chromatography.
도 8은 세파덱스 LH-20 컬럼 크로마토그래피에 의해 용출된 각 분획별 우레아제 저해활성을 측정하여 나타낸 것이다.Figure 8 shows the measured urease inhibitory activity of each fraction eluted by Sephadex LH-20 column chromatography.
도 9는 RCW2-Ⅲcα의 워터스 프로틴 팩 60SW 컬럼크로마토그래피의 용출결과를 나타낸 것이다.Figure 9 shows the elution results of Waters Protein Pack 60SW column chromatography of RCW2-IIIcα.
도 10은 RCW2-Ⅲcα의 HPLC 실행 결과를 나타낸 것이다.10 shows the results of HPLC execution of RCW2-IIIcα.
도 11은 RCW2의 가열조건에 따른 우레아제 저해 활성을 측정하여 나타낸 것이다.Figure 11 shows the measurement of the urease inhibitory activity according to the heating conditions of RCW2.
도 12는 RCW2의 농도별 펩신 처리후의 RCW2의 우레아제 저해활성을 측정하여 나타낸 것이다.Figure 12 shows the measured urease inhibitory activity of RCW2 after pepsin treatment by concentration of RCW2.
본 발명은 생약소재인 복분자, 녹차잎, 두충껍질, 구기자를 용매추출하거나, 냉수추출 또는 열수추출한 추출물들의 군(group)에서 선택되는 추출물을 적어도 1종 이상을 포함하며, 헬리코박터 파이로리 우레아제 저해활성을 가지는 것을 특징으로 하는 생약추출물을 제공한다.The present invention comprises at least one or more extracts selected from the group of extracts extracted from herbal extracts of bokbunja, green tea leaves, haricot peel, goji sol, cold water or hot water extract, and inhibits the Helicobacter pylori urease inhibitory activity It provides a herbal extract characterized in that it has.
또한, 본발명은 상기 용매추출에 있어서 아세톤, 메탄올, 에탄올 또는 이소프로필알코올을 용매로 사용하고, 에틸아세테이트로 분획하여 얻은, 헬리코박터 파이로리 우레아제 저해활성을 가지는 것을 특징으로 하는 생약추출물을 제공한다.In addition, the present invention provides a herbal extract, characterized in that having a Helicobacter pylori urease inhibitory activity obtained by fractionation with ethyl acetate using acetone, methanol, ethanol or isopropyl alcohol as a solvent in the solvent extraction.
특히 상기 아세톤 용매는 70% 아세톤인 것이 바람직하다.In particular, the acetone solvent is preferably 70% acetone.
또한, 본발명은 상기 에틸아세테이트로 분획하여 얻은 생약추출물을 부탄올을 사용하여 재분획하여 얻은, 헬리코박터 파이로리 우레아제 저해활성을 가지는 것을 특징으로 하는 생약추출물을 제공한다.In another aspect, the present invention provides a herbal extract, characterized in that having a helicobacter pylori urease inhibitory activity obtained by re-fractionation of the herbal extract obtained by fractionation with the ethyl acetate using butanol.
또한, 본발명은 아세톤, 메탄올, 에탄올 또는 이소프로필알코올 용매의 생약추출물을 에틸아세테이트, 부탄올로 순차적으로 분획하고, 이를 DEAE-토요펄 650C 컬럼크로마토그래피, 부틸-토요펄 65M 컬럼크로마토그래피 및/또는 세파덱스 LH-20 컬럼크로마토그래피로 재분획하여 얻은, 헬리코박터 파이로리 우레아제 저해활성을 가지는 것을 특징으로 하는 생약추출물을 제공한다.In addition, the present invention sequentially fractionated the crude extract of acetone, methanol, ethanol or isopropyl alcohol solvent into ethyl acetate, butanol, and DEAE-Toyo Pearl 650C column chromatography, butyl-Toyo Pearl 65M column chromatography and / or It provides a herbal extract characterized by having Helicobacter pylori urease inhibitory activity, which is obtained by refraction by Sephadex LH-20 column chromatography.
본발명에 따른 복분자, 녹차잎, 두충껍질, 구기자 추출물은 발효유, 음료 등의 기능성 식품의 소재 또는 약학제재의 소재로 이용될 수 있다.Bokbunja, green tea leaves, tofu peel, Gojija extract according to the present invention can be used as a material of functional foods or pharmaceutical preparations such as fermented milk, beverages.
생약소재Herbal medicine
1. 복분자1. Bokbunja
복분자는 복분자딸기(Rubus coreanus)의 열매를 말하며, 복분자딸기는 장미과에 속하는 낙엽관목으로써 산록 양지에서 자라고, 높이는 3m 정도이고, 끝이 휘어져서 땅에 닿으면 뿌리가 내리며, 줄기는 자줏빛이 도는 붉은 색이며 새로 나는 가지에는 흰가루가 있다. 5~6월에 연한 홍색 꽃이 핀다. 복분자는 제주, 전남, 충남, 충북, 경남, 황해도에 야생하며, 지리적으로는 중국, 일본에 분포한다. 한방에서는 보간신(補肝腎), 명목, 이뇨제, 강장약으로 사용된다.Bokbunja is the fruit of Rubus coreanus. Bokbunja strawberry is a deciduous shrub belonging to Rosaceae. It grows in the hilly forest, it is about 3m high, and its root is bent when reaching the ground, and the stem is purplish red. It is colored and has new white branches. Light red flowers bloom in May-June. Bokbunja are wild in Jeju, Jeonnam, Chungnam, Chungbuk, Gyeongnam, and Hwanghae, and geographically distributed in China and Japan. In oriental medicine, it is used as interpolation, nominal, diuretic and tonic medicine.
2. 녹차잎2. Green Tea Leaves
차나무(Thea sinensis)의 어린 잎을 따서 즉시 가열하여 산화효소를 파괴시킨 후 가열하여 수분을 증발시킴으로써 초록색의 바삭바삭한 녹차잎을 만든다. 녹차는 각성, 강심, 이뇨, 해독작용 등이 있는 것으로 알려져 왔다.After picking the young leaves of Thea sinensis, they are immediately heated to destroy oxidase and heated to evaporate moisture to create green crunchy green tea leaves. Green tea has been known to have arousal, heart, diuresis, detoxification.
3. 두충껍질3. Peeled Peel
두충(Eucommia ulmoides)은 두충과에 속하는 높이 10m정도의 낙엽활목 교목이며, 산과 들에서 자라는 식물이다. 한방에서 나무껍질을 보약·강장제로 쓰는데, 대뇌를 튼튼히 하고 폐와 무릎앓이, 음습증을 다스리는 것으로 알려져 있다.Eucommia ulmoides is a deciduous tree plant of about 10m in height belonging to the genus Camellia, which is a plant that grows in mountains and fields. The bark is used as a medicine and tonic in herbal medicine. It is known to strengthen the brain and to control lung and knee pain and hydration.
4. 구기자4. Wolfberry
구기자(Lycium chinense)는 구기자나무의 열매를 말린 것으로서 강장제로 사용된다.Lycium chinense is the dried fruit of the wolfberry tree and is used as a tonic.
이하, 본 발명의 바람직한 실시예에 대해 상세히 설명한다. 그러나, 다음 실시예에 의해 본 발명이 한정되는 것은 아니며, 본 발명의 기술적 사상의 범위내에서 당업자에 의한 통상적인 변형예가 가능하다.Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited by the following examples, and conventional modifications by those skilled in the art are possible within the scope of the technical idea of the present invention.
생약소재의 추출방법Extraction method of herbal medicine material
실시예1Example 1
생약소재의 아세톤추출Acetone Extraction of Medicinal Herbs
도 1은 복분자 추출물의 용매분획 과정을 나타낸 흐름도로서, 본 도면을 참조하여 본 발명의 실시예1에 대해 상세히 설명하기로 한다.1 is a flow chart illustrating a solvent fractionation process of bokbunja extract, with reference to the drawings will be described in detail with respect to the first embodiment of the present invention.
복분자 조말(10)을 시료로 하여 100℃에서 5분간 블랜칭(blanching)하여 생세포내 효소를 불활성시키고 동결건조하여 수분을 완전히 제거하였다.Using bokbunja powder (10) as a sample for 5 minutes at 100 ° C (blanching) to inactivate the enzyme in the living cells and lyophilized to completely remove the moisture.
수분을 제거한 시료에 적당량의 증류수를 넣고 5,000 rpm에서 5분, 6,000rpm에서 5분, 7,000rpm에서 20분간 호모게나이저를 사용하여 파쇄한 후 5,000 x g에서 20분간 원심분리하여 얻은 침전물을 동결건조하여 수분을 완전히 제거하였다. 수분이 제거된 침전물을 70% 아세톤 10배 부피에 분산하여, 2주 동안 스탠딩(Standing) 추출한 후 감압농축, 동결건조하여 70% 아세톤 추출물(RC)(20)을 얻었다.After adding the appropriate amount of distilled water to the sample from which the water was removed, the product was crushed using a homogenizer for 5 minutes at 5,000 rpm, 5 minutes at 6,000 rpm, and 20 minutes at 7,000 rpm. The precipitate obtained by centrifugation at 5,000 xg for 20 minutes was lyophilized. Water was completely removed. The water-free precipitate was dispersed in a 10% volume of 70% acetone, and then extracted for 2 weeks, then concentrated under reduced pressure and lyophilized to obtain 70% acetone extract (RC) (20).
수득한 복분자추출물(RC)(20)을 증류수에 분산시키고, 증류수와 동일한 양의 에틸아세테이트을 부가하여 원심분리로 분획한 후 증류수층을 감압농축하여 물분획1(RCW1)(30)을 얻었다. 이렇게 얻은 물분획1(RCW1)(30)에 다시 증류수와 동일한 양의 부탄올을 부가하여 원심분리로 분획한 후 증류수층을 감압 농축하여 물분획2(RCW2)(40)을 얻었다.The obtained bokbunja extract (RC) 20 was dispersed in distilled water, ethyl acetate was added in the same amount as distilled water and fractionated by centrifugation. The distilled water layer was concentrated under reduced pressure to obtain a water fraction 1 (RCW1) (30). Water fraction 1 (RCW1) (30) thus obtained was added to the same amount of butanol as distilled water again and fractionated by centrifugation. The distilled water layer was concentrated under reduced pressure to obtain water fraction 2 (RCW2) (40).
실시예 2Example 2
생약소재의 메탄올 추출Methanol Extraction of Medicinal Herbs
생약소재의 메탄올 추출방법은, 추출용매로 메탄올을 사용하는 것을 제외하고는 실시예1의 아세톤 추출방법과 동일하다.The methanol extraction method of the herbal material is the same as the acetone extraction method of Example 1 except that methanol is used as the extraction solvent.
실시예 3Example 3
생약소재의 에탄올 추출Ethanol Extraction of Medicinal Herbs
생약소재의 에탄올 추출방법은, 추출용매로 에탄올을 사용하는 것을 제외하고는 실시예1의 아세톤 추출방법과 동일하다.The ethanol extraction method of the herbal material is the same as the acetone extraction method of Example 1, except that ethanol is used as the extraction solvent.
실시예 4Example 4
생약소재의 이소프로필알코올 추출Isopropyl Alcohol Extraction from Medicinal Herbs
생약소재의 이소프로필알코올 추출방법은, 추출용매로 이소프로필알코올을 사용하는 것을 제외하고는 실시예1의 아세톤 추출방법과 동일하다.The isopropyl alcohol extraction method of the herbal material is the same as the acetone extraction method of Example 1, except that isopropyl alcohol is used as the extraction solvent.
실시예 5Example 5
생약소재의 냉수추출Cold water extraction of herbal ingredients
복분자 조말을 시료로 하여 100℃에서 5분간 블랜칭(blanching)하여 생세포내 효소를 불활성시키고 동결건조하여 수분을 완전히 제거하였다.Using bokbunja powder as a sample, it was blanched at 100 ° C. for 5 minutes to inactivate live cell enzymes and lyophilize to completely remove moisture.
수분을 제거한 시료에 적당량의 증류수를 넣고 5,000 rpm에서 5분, 6,000rpm에서 5분, 7,000rpm에서 20분간 호모게나이저를 사용하여 파쇄한 후 5,000 x g에서 20분간 원심분리하여 얻은 상등액을 동결건조하여 냉수추출물을 얻었다.After adding the appropriate amount of distilled water to the sample from which the water was removed, the mixture was crushed using a homogenizer for 5 minutes at 5,000 rpm, 5 minutes at 6,000 rpm, and 20 minutes at 7,000 rpm. The supernatant obtained by centrifugation at 5,000 xg for 20 minutes was lyophilized. Cold water extract was obtained.
실시예 6Example 6
생약소재의 열수추출Hydrothermal Extraction of Herbal Medicines
복분자 조말을 시료로 하여 100℃에서 5분간 블랜칭(blanching)하여 생세포내 효소를 불활성시키고 동결건조하여 수분을 완전히 제거하였다.Using bokbunja powder as a sample, it was blanched at 100 ° C. for 5 minutes to inactivate live cell enzymes and lyophilize to completely remove moisture.
수분을 제거한 시료에 적당량의 증류수를 넣고 5,000 rpm에서 5분, 6,000rpm에서 5분, 7,000rpm에서 20분간 호모게나이저를 사용하여 파쇄한 후 5,000 x g에서 20분간 원심분리하여 얻은 침전물을 동결건조하여 열수(hot water)에 2시간동안 환류추출한 후 상등액을 동결건조하여 열수추출물을 얻었다.After adding the appropriate amount of distilled water to the sample from which the water was removed, the product was crushed using a homogenizer for 5 minutes at 5,000 rpm, 5 minutes at 6,000 rpm, and 20 minutes at 7,000 rpm. The precipitate obtained by centrifugation at 5,000 xg for 20 minutes was lyophilized. After refluxing in hot water for 2 hours, the supernatant was lyophilized to obtain a hot water extract.
여기서는 복분자를 이용하여 생약을 추출하는 방법에 대하여만 설명하였으나, 기술한 생약소재인 녹차잎, 구기자 및, 두충껍질로부터도 위와 동일한 공정에 의하여 생약추출물을 얻을 수 있다. 따라서, 그에 대한 설명은 생략하고, 각 추출물의 헬리코박터 우레아제 저해활성 측정결과만을 후기되는 표 1에 도시하였다.Here, only the method of extracting the herbal medicine using bokbunja, but the herbal medicine extract can be obtained by the same process from the green tea leaves, wolfberry, and haricot peel which are the herbal ingredients described above. Therefore, the description thereof is omitted, it is shown in Table 1 which only the results of measuring the Helicobacter urease inhibitory activity of each extract.
추출물의 헬리고박터 파이로리 우레아제 저해활성의 측정Determination of Helicobacter pylori urease Inhibitory Activity of Extracts
실시예 7Example 7
추출물의 저해활성은 우레아제가 생산해 낸 암모니아가 페놀/니트로프루시드(phenol/nitroprusside)와 알카린 하이포클로라이트(alkaline hyphochlorite)에 의해 인도페놀(indophenol)로 전환되는 양을 에세이계를 사용하여 측정하였다.The inhibitory activity of the extract was measured using an essay measuring the amount of urease-produced ammonia converted to phenol / nitroprusside and alkaline hyphochlorite by indophenol. .
추출물 시료 6㎕와 우레아제 20㎕를 37℃에서 5분 프리인큐베이션(preincubation)시킨 후, 요소액 40㎕를 가하여 37℃에서 20분간 인큐베이션(incubation)한 후 페놀/니트로프루시드 1,000㎕와 알카린 하이포클로라이트 1,000㎕를 가하여 동일온도에서 30분간 반응시켜 A590에서 흡광도를 측정하였고,하기 식에 따라 % 저해 활성을 환산하였다.6 μl of the extract sample and 20 μl of urease were preincubated at 37 ° C. for 5 minutes, then 40 μl of urea solution was incubated at 37 ° C. for 20 minutes, followed by 1,000 μl of phenol / nitroprusside and alkaline hypophore. 1,000 μl of chlorite was added and reacted at the same temperature for 30 minutes to measure absorbance at A 590. The % inhibition activity was calculated according to the following formula.
ureaseurease
Urea + H2O ---→ 2NH3+ CO2 Urea + H 2 O --- → 2NH 3 + CO 2
NH3 + 2NaClO ---→ 2NH2Cl + 2NaOHNH3 + 2NaClO --- → 2NH2Cl + 2NaOH
2Phenol + 2NH2Cl + 2OH- ---→ 2,4-aminophenol + 2Cl- + 2H2O2Phenol + 2NH2Cl + 2OH- --- → 2,4-aminophenol + 2Cl- + 2H2O
2,4-Aminophenol + 2phenlo +O2 ---→ 2indophenol + 2H2O2,4-Aminophenol + 2phenlo + O2 --- → 2indophenol + 2H2O
헬리코박터 파이로리의 저해활성 (%) = [1-(As-Ab)/(Ac-Ab)] ×100Inhibitory Activity of Helicobacter Pylori (%) = [1- (As-Ab) / (Ac-Ab)] × 100
As : 생약추출물로 처리한 우레아제의 흡광도As: absorbance of urease treated with herbal extracts
Ab : 변성우레아제 흡광도Ab: denatured urease absorbance
Ac : 생약추출물로 처리하지 않은 우레아제 흡광도Ac: urease absorbance not treated with herbal extracts
가장 효율적인 생약추출방법을 확인하기 위해, 실시예5에 따라, 실시예1, 2, 3 및 4의 방법으로 수득한 복분자, 녹차잎, 두충껍질, 구기자 추출물의 헬리코박터 파이로리 우제아제 저해활성을 측정한 결과를 하기의 표1에 도시하였다. 측정결과, 70% 아세톤추출이 가장 바람직하나, 메탄올추출, 냉수추출, 열수추출에 의한 추출물도 비교적 높은 우레아제 저해 활성을 나타냈으며, 특히 구기자는 메탄올추출물이 70% 아세톤추출물보다 높은 우레아제 저해활성을 나타냈다.In order to identify the most effective herbal extract method, according to Example 5, the Helicobacter pylori uragease inhibitory activity of Bokbunja, Green Tea Leaves, Peel Peel, and Gojija extracts obtained by the methods of Examples 1, 2, 3 and 4 were measured. The results are shown in Table 1 below. As a result, 70% acetone extract was the most preferable, but the extract by methanol extraction, cold water extraction, and hot water extraction also showed relatively high urease inhibitory activity. Especially, wolfberry showed higher urease inhibitory activity than methanol extract by 70% acetone extract. .
(단위: %)(unit: %)
실시예1에서 수득한 복분자의 70% 아세톤용매추출물 RC , RCW1 및 RCW2의 우레아제 저해활성을 실시예 6의 방법으로 측정한 결과, 도2에서 도시된 바와 같이, RCW1에서 28.75%, RCW2에서 32.62%의 활성을 보였다.The urease inhibitory activity of the 70% acetone solvent extracts RC, RCW1 and RCW2 of bokbunja obtained in Example 1 was measured by the method of Example 6, and as shown in FIG. 2, 28.75% in RCW1 and 32.62% in RCW2. Showed activity.
활성물질의 분리정제Separation and purification of active substance
생약추출물에 함유된 활성물질의 화학적 성질을 밝히고, 활성물질의 순도를 높이기 위해 하기와 같은 분리정제과정을 실시하였다.In order to clarify the chemical properties of the active substance contained in the herbal extracts and to increase the purity of the active substance, the following separate purification process was carried out.
하기 실시예는 우레아제 저해 활성이 가장 높은 복분자추출물을 대상으로 하였으나, 타 생약소재들도 다음과 같은 방법으로 분리정제할 수 있다.The following example was targeted to the bokase extract with the highest urease inhibitory activity, but other herbal materials can be separated and purified by the following method.
실시예 8Example 8
활성물질의 분리정제를 위한 전단계로, 저해활성본체가 단백질에 기인하는 것인지 다당에 기인하는 것인지 확인하기 위해 RCW2를 사용하여 다음과 같은 방법으로 프로나제(pronase) 소화물 및 과옥소산(periodate) 산화물을 조제하였다.As a preliminary step for the purification of the active substance, pronase digestion and periodate oxides are used in the following manner using RCW2 to determine whether the inhibitory active body is protein- or polysaccharide-based. Was prepared.
프로나제소화물의 조제Preparation of Pronase Digestion
20mg의 RCW2를 10mM 염화칼슘이 함유된 50mM Tris-HCl 완충용액 (pH 7.5) 50mL에 용해시킨 후, 12mg의 프로나제를 가하여 37℃에서 48시간 동안 반응시켰다. 20 mg of RCW2 was dissolved in 50 mL of 50 mM Tris-HCl buffer solution (pH 7.5) containing 10 mM calcium chloride, and then 12 mg of pronase was added and reacted at 37 ° C. for 48 hours.
반응정지를 위해 5분간 가열한 후 원심분리하여 침전물을 제거한 다음 상등액을 투석, 동결건조하여 프로나제소화물을 조제하였다.After the reaction was stopped for 5 minutes and centrifuged to remove the precipitate, the supernatant was dialyzed and lyophilized to prepare a pronase digest.
과옥소산 산화물의 조제Preparation of Oxygen Peroxate
20 mg의 RCW2를 50 mM 아세테이트 완충액 (pH4.5) 50 mL에 녹인 후, 50 mM 과요오드산나트륨(sodium metaperiodate(NaIO4))을 가한 혼합물을 4℃ 암소(暗所)에서 3일간 교반, 방치하였다. 그런 다음, 잔여 과옥소산을 제거하기 위해 반응액에 에틸렌글리콜 5 mL를 첨가한 후 투석하고, 비투석 획분을 약 10 mL까지 농축하였다. 이 농축액에 20mg의 과붕소산나트륨(NaBH4)을 가하여 실온에서 12시간 교반하여 환원시킨 후 중화, 투석하고, 비투석 획분을 동결건조하여 과옥소산 산화물을 조제하였다.After dissolving 20 mg of RCW2 in 50 mL of 50 mM acetate buffer (pH4.5), the mixture with 50 mM sodium metaperiodate (NaIO4) was added and stirred and left for 3 days at 4 ° C in the dark. It was. Then, 5 mL of ethylene glycol was added to the reaction solution to remove residual peroxo acid, followed by dialysis, and the non-dialysis fraction was concentrated to about 10 mL. 20 mg of sodium perborate (NaBH 4 ) was added to the concentrate, stirred at room temperature for 12 hours to reduce the weight, and neutralized and dialyzed. The non-dialysis fraction was lyophilized to prepare an oxide of peroxate.
결과result
상기 프로나제 소화물과 과옥소산 산화물의 헬리코박터 우레아제 저해활성을 실시예7에 따라 측정한 결과 도3과 같이 프로나제 소화물은 1.23%, 과옥소산 산화물은 23.02%의 활성을 보였다. 이 결과로부터 활성본체가 탄수화물이 아닌 단백질성 물질이라는 것을 추정할 수 있었다.Helicobacter urease inhibitory activity of the pronase digestion and peroxo acid oxide was measured according to Example 7, and as shown in FIG. 3, the pronase digestion showed 1.23% and 23.02% peroxate oxide activity. From these results, it could be estimated that the active body is a proteinaceous substance rather than a carbohydrate.
실시예 9Example 9
이온교환 컬럼 크로마토그래피(Ion-exchange colum chromatography)의 실시Ion exchange column chromatography
헬리코박터 파이로리 우레아제에 대하여 높은 활성을 보인 RCW2를 증류수에 용해한 다음, 50mM 인산칼륨 완충용액(pH 7.0)으로 평형화된 DEAE-토요펄 650C 컬럼(Diethylaminoethyl-Toyopearl 650C colum chromatography)(Cl- form, 3.8 ×40cm)에 흡착시킨 후, 0, 0.5, 1, 1.5, 2M 농도의 염화나트륨(NaCl)이 함유된 완충용액을 사용하여 단계적으로 용출시켜 5개의 획분(RCW2-Ⅰ, Ⅱ, Ⅲ, Ⅳ, Ⅴ)을 얻었다. 이렇게 얻은 각 획분을 50mM 인산칼륨 완충용액(pH 7.0)으로 투석, 감압농축 및 동결 건조하여 1mg/mL의농도로 조제하여 활성측정용 시료로 사용하였다. 각 획분의 우레아제 저해활성을 실시예6에 따라 측정한 결과를 도4에 도시하였다. 결과로부터 1M 염화나트륨에서 용출된 획분(RCW2-Ⅲ)이 54.97%로 가장 활성이 높음을 알 수 있었다. 1M 염화나트륨의 비교적 높은 이온농도에서 용출된 획분이 높은 활성을 보임으로써 활성물질은 비교적 강한 이온성 물질임을 알 수 있었다.RCW2, which shows high activity against Helicobacter pylori urease, was dissolved in distilled water and then DEAE-Toyopearl 650C column (Cl-form, 3.8 × 40 cm) equilibrated with 50 mM potassium phosphate buffer (pH 7.0). ) And eluted stepwise using a buffer solution containing sodium chloride (NaCl) at concentrations of 0, 0.5, 1, 1.5, and 2M to give five fractions (RCW2-I, II, III, IV, V). Got it. Each fraction thus obtained was dialyzed with 50 mM potassium phosphate buffer (pH 7.0), concentrated under reduced pressure, and lyophilized to a concentration of 1 mg / mL, and used as a sample for activity measurement. The result of measuring the urease inhibitory activity of each fraction according to Example 6 is shown in FIG. The results showed that the fraction (RCW2-III) eluted from 1M sodium chloride was the highest with 54.97%. The fraction eluted at a relatively high ionic concentration of 1M sodium chloride showed high activity, indicating that the active material is a relatively strong ionic material.
실시예 10Example 10
소수성 상호작용 컬럼 크로마토그래피(Hydrophobic interaction chromatography)의 실시Hydrophobic Interaction Chromatography
DEAE-토요펄 650C 컬럼 (Cl- form)의 분획결과 가장 활성이 높았던 RCW2-Ⅲ을 부틸-토요펄 650M 컬럼(Butyl-Toyopearl 650M colum)을 사용하여 소수성 상호작용 컬럼 크로마토그래피를 실시하였다. 30% 포화황산암모늄용액으로 평형화시킨 후, 포화황산암모늄용액 30%에서 0%까지 직선농도구배를 사용하여 용출한 결과 RCW2-Ⅲa, Ⅲb, Ⅲc의 3개의 획분을 분리할 수 있었고, 그 결과를 도5에 도시하였다. 각 획분의 우레아제 저해활성을 실시예5에 따라 측정한 결과는 도6에 도시된 바와 같으며, 0% 포화황산암모늄용액의 농도에서 용출된 RCW2-Ⅲc가 69.53%로 가장 높은 활성을 보임으로써 활성물질이 소수성이 높은 물질임을 알 수 있었다.Hydrophobic interaction column chromatography was carried out using a butyl-Toyopearl 650M column (Butyl-Toyopearl 650M colum) for the most active RCW2-III as a fraction of the DEAE-Toyopearl 650C column (Cl- form). After equilibrating with 30% saturated ammonium sulphate solution, eluting with a straight tool from 30% saturated ammonium sulphate solution to 0%, three fractions of RCW2-IIIa, IIIb, and IIIc were separated. 5 is shown. The result of measuring the urease inhibitory activity of each fraction according to Example 5 is as shown in FIG. 6, and the activity of RCW2-IIIc eluted at the concentration of 0% saturated ammonium sulfate solution showed the highest activity as 69.53%. It was found that the material was a high hydrophobic material.
실시예 11Example 11
겔 필트레이션 크로마토그래피 (Gel filtration chromatography)의 실시Conducting Gel Filtration Chromatography
부틸-토요펄 650M 컬럼크로마토그래피에서 가장 활성이 높은 RCW2-Ⅲc의 소수성 획분을 20% 메탄올 조건으로 평형화된 세파덱스 LH-20 컬럼(18 ×00cm)에 상기의 동결건조물을 20% 에탄올에 활성획분을 주입하고 12mL/hr의 유속을 1mL씩 용출분획하여 그 결과를 도7에 도시하였다. 수득된 용출물의 헬리코박터 우레아제 저해활성을 실시예7의 방법으로 측정하여 도8에 도시하였다. RCW2-Ⅲcα에서 가장 높은 활성을 나타냄을 알 수 있었다.The lyophilisate was activated in 20% ethanol on a Sephadex LH-20 column (18 × 00 cm) equilibrated with 20% methanol in the most hydrophobic fraction of RCW2-IIIc, the most active in butyl-Toyopearl 650M column chromatography. Was injected and the fractions were eluted at a flow rate of 12 mL / hr by 1 mL. Helicobacter urease inhibitory activity of the obtained eluate was measured by the method of Example 7 and shown in FIG. RCW2-IIIcα showed the highest activity.
실시예 12Example 12
정제물질의 순도Purity of Purified Material
세파덱스 LH-20 컬럼 크로마토그래피에 의한 용출물 중 가장 높은 활성을 나타낸 RCW2-Ⅲcα의 순도를 확인하기 위하여 고능률 액상 크로마토그래피(High performance liquid chromatography : HPLC)를 행하였다.High performance liquid chromatography (HPLC) was performed to confirm the purity of RCW2-IIIcα exhibiting the highest activity in the eluate by Sephadex LH-20 column chromatography.
워터스 프로틴 팩 60SW(7.8 ×00mm) GPC(gel permeation chromathgraphy) 컬럼을 이용하여 50% 메탄올을 이동상으로 HPLC를 행한 결과, 도8에 도시된 바와 같이 좌우대칭인 단일피크를 나타냄으로써, 세파덱스 LH-20 컬럼 크로마토그래피에 의해 용출된 RCW2-Ⅲcα는 비교적 순도가 높은 물질임을 알 수 있었다. 정제물질로 확인된 RCW2-Ⅲcα는 70% 아세톤 추출물의 20% 저해활성에 비해 약95%의 활성을 나타냄으로써 5배 정도의 정제도로 정제되었음을 알 수 있었다.HPLC of 50% methanol in mobile phase using a Waters Protein Pack 60SW (7.8 x 00 mm) gel permeation chromathgraphy (GPC) column showed Sepadex LH- by showing a single peak symmetrically as shown in FIG. RCW2-IIIcα eluted by 20 column chromatography was found to be a relatively high purity material. RCW2-IIIcα identified as a purified material showed about 95% of the activity compared to the 20% inhibitory activity of the 70% acetone extract.
실시예 13Example 13
정제물질의 분자량Molecular Weight of Purified Material
최종정제물질인 RCW2-Ⅲcα를 워터스 프로틴 팩 60SW(7.8 ×00mm) GPC(gel permeation chromatography) 컬럼에 50% 메탄올을 이동상으로 하고, 브래드키닌(bradykinin)(분자량 : 1,282.5 Da), 아프로티닌(aprotinin)(분자량 : 6,512 Da), 사이토크론 c(cytochrone c)(분자량 : 12,384 Da), 리보뉴클레아제(ribonuclease)(분자량 13,700 Da)를 표준물질로 사용하여 HPLC를 실행한 결과를 도10에 도시하였다. 표준단백질과 비교 측정한 결과 활성물질의 분자량은 약 13kDa이라는 것을 알았다.RCW2-IIIcα, the final purification material, was used as a mobile phase with 50% methanol in a Waters Protein Pack 60SW (7.8 × 00 mm) GPC (gel permeation chromatography) column, and Bradykinin (molecular weight: 1,282.5 Da) and aprotinin (Molecular weight: 6,512 Da), cytokron c (cytochrone c) (molecular weight: 12,384 Da), ribonuclease (ribonuclease) (molecular weight: 13,700 Da) the results of HPLC was shown in Figure 10 . Comparative measurements with standard proteins revealed that the active material had a molecular weight of about 13 kDa.
다음은 기능성 식품으로의 실용화 가능성을 검토하기 위해, 추출물의 열안정성, 소화효소에의 안정성을 실험하는 과정이다. 하기 실시예는 우레아제의 저해 활성이 가장 높은 복분자추출물을 대상으로 하였으나, 타 생약소재들도 다음과 같은 방법으로 안정성 등을 시험할 수 있다.The following is a process to test the stability of the extract and its thermal stability and digestive enzymes in order to examine the possibility of practical use as a functional food. The following example was targeted to the bokbunja extract with the highest inhibitory activity of urease, other herbal materials can also be tested for stability in the following manner.
실시예 14Example 14
정제물질의 열안정성Thermal Stability of Purified Materials
억제 활성물질의 소재화 적성 중 열에 대한 안정성을 확인하기 위해 RCW2를 각각 30℃, 70℃, 100℃에서 10분과 30분씩 가열한 후, 억제활성을 실시예2에 따라 측정하고 그 결과를 도11에 도시하였다. 도11에서 대조군은 가열처리하지 않은RCW2로 하였다. 도11에서 보는 바와 같이 30℃, 70℃에서는 거의 활성이 감소되지 않았고, 100℃에서는 10분에서는 94%, 30분에서는 97% 활성이 감소되었다. 결과로부터 억제활성물질은 내열성 물질임을 알 수 있었다.In order to confirm the stability to heat during materialization aptitude of the inhibitory active material, RCW2 was heated at 30 ° C, 70 ° C, and 100 ° C for 10 minutes and 30 minutes, respectively, and the inhibitory activity was measured according to Example 2, and the results are shown in FIG. Shown in In FIG. 11, the control group was RCW2 without heat treatment. As shown in Fig. 11, the activity was hardly decreased at 30 ° C. and 70 ° C., but the activity was decreased by 94% at 10 minutes and 97% at 30 minutes at 100 ° C. The results showed that the inhibitory active material was a heat resistant material.
실시예 15Example 15
정제물질에 대한 소화효소의 영향Effect of Digestive Enzymes on Purified Substances
정제된 펩티드성 물질을 기능성 식품용으로 소재화하기 위해서는 위내 소화관에서 이들 정제물질이 분해됨이 없이 흡수되고, 또한 위내의 효소들에 의해서도 안정성을 유지해야 한다.In order to materialize the purified peptide material for functional foods, these purified substances must be absorbed in the gastrointestinal digestive tract without being degraded and also maintained by enzymes in the stomach.
본 발명에서 분리한 우레아제 저해물질에 대하여 전형적인 위내 단백분해효소인 펩신의 가수분해성을 검토함으로써 이 저해 물질이 경구투여 후 위내에서 흡수될 때까지의 저해 활성 유지여부를 다음과 같이 시험관 내(in vitro)에서 검토하였다.By examining the hydrolyzability of pepsin, a typical gastric protease, against the urease inhibitor isolated from the present invention, whether or not the inhibitor was maintained until the absorption was absorbed into the stomach after oral administration was performed in vitro as follows. ).
RCW2를 각각 0.1mg/mL, 0.2mg/mL, 0.3mg/mL 의 농도별 펩신을 처리한 후, 실시예2의 우레아제 에세이 시스템을 적용하여 활성물질의 저해 활성을 검토한 결과를 도12에 도시하였다. 도12에서 대조군은 펩신을 처리하지 않은 RCW2로 하였다. 도12에 도시된 바와 같이 0.1mg/mL의 펩신을 처리한 RCW2는 26%, 0.2mg/mL의 펩신을 처리한 RCW2는 21.5%, 0.3mg/mL의 펩신을 처리한 RCW2는 약17.5%의 저해활성을 나타냄으로써 정제물질이 펩신에 안정한 물질임을 알 수 있었다.RCW2 was treated with pepsin at concentrations of 0.1 mg / mL, 0.2 mg / mL, and 0.3 mg / mL, respectively, and the inhibitory activity of the active substance was examined by applying the urease assay system of Example 2, as shown in FIG. 12. It was. In FIG. 12, the control group was RCW2 not treated with pepsin. As shown in FIG. 12, 26% of RCW2 treated with 0.1 mg / mL pepsin, 21.5% of RCW2 treated with 0.2 mg / mL pepsin, and about 17.5% of RCW2 treated with 0.3 mg / mL pepsin By showing inhibitory activity, it was found that the purified material was stable to pepsin.
발효유, 음료, 약학제재의 제조Fermented Milk, Beverages, Pharmaceuticals
상기 추출물 또는 정제물질을 함유하는 발효유, 음료 또는 약학제재의 제조는 하기와 같은 방법으로 실시될 수 있다. 생약추출물은 정제도가 높은 추출물일수록 효능면에서 바람직하나, 하기 실시예에서는 실용화 단계의 경제적인 면을 고려하여, 70% 아세톤용매출출물 중 에틸아세테이트 추출단계의 물분획층을 사용하였다.Fermented milk, beverage or pharmaceutical preparation containing the extract or purified material may be carried out by the following method. The herbal extracts are more preferable in terms of efficacy as the extract having a higher degree of purification, but in the following examples, the water fraction layer of the ethyl acetate extracting step of the 70% acetone solvent extract was used in consideration of the economic aspect of the commercialization step.
실시예 16Example 16
발효유의 제조Preparation of Fermented Milk
탈지분유를 이용하여 무지유 고형분 함량을 15.5~16 중량%로 조정한 농축 원료유에 설탕 등의 원료를 혼합하여 가온 용해한 후, 한천 , 젤라틴, 펙틴 중에서 선택된 1종 이상의 안정제를 적정량 첨가하여 균질화 하였다.Using skim milk powder, raw materials such as sugar were mixed and heated and dissolved in concentrated raw milk having a non-fat solid content of 15.5 to 16 wt%, and then homogenized by adding an appropriate amount of one or more stabilizers selected from agar, gelatin, and pectin.
이를 85℃에서 30분 또는 90~95℃에서 5~10분간 가열하여 살균하였다. 상기 살균된 원료유를 일정온도까지 40~45℃까지 냉각한 후, 유산균 스타터를 2% 접종하고, 40~42℃에서 4시간 배양하였다. 배양 후 온도를 4~5℃로 급속히 냉각하여 유산균의 증식을 억제함으로써 발효유의 산도를 pH 4.5로 맞추었다.It was sterilized by heating at 85 ° C. for 30 minutes or at 90-95 ° C. for 5-10 minutes. After cooling the sterilized raw material oil to a constant temperature to 40 ~ 45 ℃, 2% of the lactic acid bacteria starter was inoculated, and incubated at 40 ~ 42 ℃ 4 hours. After incubation, the temperature was rapidly cooled to 4-5 ° C. to inhibit the growth of lactic acid bacteria, thereby adjusting the acidity of the fermented milk to pH 4.5.
상기 발효유에 복분자 추출물, 녹차잎, 두충껍질, 구기자 추출물 중, 1종 이상을 0.1 ~ 0.5 중량% 혼합하고, 그 외 적절한 첨가물, 예컨대, 물, 비타민, 식이섬유, 포도당 등을 첨가한 후 교반하여 균질화 시킨다. 필요에 따라, 과실류, 곡류, 채소류 등을 함유할 수도 있다.The fermented milk is mixed with 0.1 ~ 0.5% by weight of one or more of the bokbunja extract, green tea leaves, tofu peel, goji berry extract, and other suitable additives, such as water, vitamins, dietary fiber, glucose, etc. Homogenize. If necessary, it may contain fruits, cereals, vegetables and the like.
실시예 17Example 17
음료의 제조Manufacture of beverages
복분자, 녹차잎, 두충껍질, 구기자 추출물 중 1종의 0.1 ~ 0.5 중량% 에 색상과당, 멸균정제수를 첨가, 혼합하고 음료용 병에 충전하여 음료를 제조하였다.Color fructose and sterile purified water were added to 0.1 ~ 0.5% by weight of one species of bokbunja, green tea leaves, tofu peel, and Goji berry extract, mixed and filled into a beverage bottle to prepare a beverage.
실시예 18Example 18
약학제재의 제조Manufacture of Pharmaceuticals
복분자, 녹차잎, 두충껍질, 구기자 추출물 중 1종 의 0.1 ~ 30 중량% 에 영양보조제(비타민, 초산에스테르, 니코틴산아미드), 부형제(올리고당, 글리코시드)를5~10%가 되도록 첨가하여 고속회전 혼합기에서 혼합하였다. 상기 혼합물에 멸균 정제수 10중량%를 첨가, 혼합하고 직경 1~2mm의 과립상으로 성형하였다. 상기 성형된 과립은 40~50℃의 진공건조기에서 건조시킨 후, 12~14 매쉬를 통과시켜 균일하게 과립을 제조하였다. 상기와 같이 제조된 과립은 적당량씩 압출성형되어 정제 또는 분말로 되거나, 경질캡슐에 충전되어 경질캡슐로 제조될 수 있다.Rotate at a high speed by adding 0.1 to 30% by weight of bokbunja, green tea leaves, tofu peel, and goji berry extract to add 5-10% of nutritional supplements (vitamins, acetate esters, nicotinamide) and excipients (oligosaccharides, glycosides). Mix in a mixer. 10% by weight of sterile purified water was added to the mixture, mixed, and molded into granules having a diameter of 1 to 2 mm. The molded granules were dried in a vacuum dryer at 40 to 50 ° C., and then passed through 12 to 14 meshes to uniformly prepare granules. The granules prepared as described above may be extruded by appropriate amounts into tablets or powders, or filled into hard capsules to produce hard capsules.
본 발명에 따르면, 복분자, 녹차잎, 두충껍질, 구기자 등의 생약 추출물은 헬리코박터 파이로리 우레아제 저해활성의 효과가 있다. 특히, 본 발명은 추출물의 정제물질은 분자량 약 13kDa의 단백질성 물질이며, 70℃, 30분의 가열에도 안정성을 보임으로써 내열성이 우수하고, 위내 단백질분해효소인 펩신에 대한 저항성도 뛰어나다. 따라서, 상기 추출물을 발효유, 음료, 약학제재 등에 함유시킴으로써 위궤양 예방 및 치료효과를 증대시킬 수 있으며, 나아가 위암의 예방에도 효과가 있는 기능성식품의 소재로 실용화할 수 있을 뿐만 아니라, 제형화하여 약학적 제제로도 활용할 수 있다.According to the present invention, herbal extracts such as bokbunja, green tea leaves, haricot peel, goji berry have the effect of Helicobacter pylori urease inhibitory activity. In particular, the purified material of the extract is a proteinaceous material having a molecular weight of about 13kDa, it is excellent in heat resistance by showing stability even after heating at 70 ℃, 30 minutes, and also excellent resistance to pepsin, a gastric protease. Therefore, by containing the extract in fermented milk, beverages, pharmaceutical preparations, etc., it is possible to increase the prevention and treatment effect of gastric ulcers, and furthermore, it can be practically used as a functional food material that is also effective in the prevention of stomach cancer, and formulated pharmaceutical It can also be used as a formulation.
Claims (17)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020020037836A KR20040003200A (en) | 2002-07-02 | 2002-07-02 | Galenical extract inhibiting Helicobacter pyroli urease activity and their use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020020037836A KR20040003200A (en) | 2002-07-02 | 2002-07-02 | Galenical extract inhibiting Helicobacter pyroli urease activity and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20040003200A true KR20040003200A (en) | 2004-01-13 |
Family
ID=37314233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020020037836A KR20040003200A (en) | 2002-07-02 | 2002-07-02 | Galenical extract inhibiting Helicobacter pyroli urease activity and their use |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20040003200A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100602841B1 (en) * | 2005-02-28 | 2006-07-19 | 고려대학교 산학협력단 | Acidic polysaccharide with cell-binding inhibition activity isolated from green tea and its composition for preventing and treating gastrointestinal diseases |
| WO2006029893A3 (en) * | 2004-09-17 | 2006-10-19 | Oystershell Nv | Composition for inhibiting or preventing the formation of a biofilm |
| KR100851962B1 (en) * | 2006-11-13 | 2008-08-12 | 주식회사 케이씨에프코리아 | Composition for anti-helicobacter pylori containing grape seed extract |
| LT5720B (en) | 2009-08-12 | 2011-04-26 | Inovativo Biomedicinas Technologiju Institūts, Sia | Fruity alimentary product with anti-microbial activity against Helicobacter pylori |
| KR101043595B1 (en) * | 2008-07-29 | 2011-06-22 | 전라북도 고창군 | Yoghurt comprising Rubus coreanus Miquel, lycopene and preparation method thereof |
| KR101521125B1 (en) * | 2013-05-08 | 2015-05-19 | (주)리즈바이오텍 | Complex plant extracts containing anti-Helicobacter pylori substance treating gastritis and preventing gastric diseaes |
| KR20180082352A (en) * | 2017-01-09 | 2018-07-18 | 남부대학교산학협력단 | Composition for Inhibiting Proliferation of Helicobacter Pylori Comprising Complex Plant Extracts and Uses Thereof |
-
2002
- 2002-07-02 KR KR1020020037836A patent/KR20040003200A/en not_active Application Discontinuation
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006029893A3 (en) * | 2004-09-17 | 2006-10-19 | Oystershell Nv | Composition for inhibiting or preventing the formation of a biofilm |
| US7691418B2 (en) | 2004-09-17 | 2010-04-06 | Oystershell Nv | Composition for inhibiting or preventing the formation of a biofilm |
| KR100602841B1 (en) * | 2005-02-28 | 2006-07-19 | 고려대학교 산학협력단 | Acidic polysaccharide with cell-binding inhibition activity isolated from green tea and its composition for preventing and treating gastrointestinal diseases |
| KR100851962B1 (en) * | 2006-11-13 | 2008-08-12 | 주식회사 케이씨에프코리아 | Composition for anti-helicobacter pylori containing grape seed extract |
| KR101043595B1 (en) * | 2008-07-29 | 2011-06-22 | 전라북도 고창군 | Yoghurt comprising Rubus coreanus Miquel, lycopene and preparation method thereof |
| LT5720B (en) | 2009-08-12 | 2011-04-26 | Inovativo Biomedicinas Technologiju Institūts, Sia | Fruity alimentary product with anti-microbial activity against Helicobacter pylori |
| KR101521125B1 (en) * | 2013-05-08 | 2015-05-19 | (주)리즈바이오텍 | Complex plant extracts containing anti-Helicobacter pylori substance treating gastritis and preventing gastric diseaes |
| KR20180082352A (en) * | 2017-01-09 | 2018-07-18 | 남부대학교산학협력단 | Composition for Inhibiting Proliferation of Helicobacter Pylori Comprising Complex Plant Extracts and Uses Thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8257761B2 (en) | Polyphenol-containing products | |
| CN1275534C (en) | Corn peptide beverage and its processing method | |
| KR20130099653A (en) | Functional vinegar containing wax gourd, chrysanthemu zawadskii and pearl shell and the method thereof | |
| KR102330828B1 (en) | Extraction method of moringa oleifera leaf and food composition containg the moringa oleifera leaf extract | |
| CN110447799A (en) | A kind of complex solid plant beverage and preparation method thereof for improving intestinal flora | |
| CN112999127B (en) | Gentiana scabra bunge compound enzyme and preparation method and application thereof | |
| KR102186766B1 (en) | Cosmetic composition containing the extracts of natural substances comprising Myosotis sylvatica, Hemerocallis Fulva and Indigofera Tinctoria | |
| CN108850345A (en) | A kind of Moringa leaf tea and preparation method thereof | |
| KR102257052B1 (en) | Manufacturing method of healthy beverage containing improvement of gastric disease by using the cabbage extracts | |
| CN115247197A (en) | Corn protein hydrolysate with helicobacter pylori adhesion antagonistic activity and preparation method and application thereof | |
| KR20040003200A (en) | Galenical extract inhibiting Helicobacter pyroli urease activity and their use | |
| CN1951236A (en) | Sialic acid drink and preparation method thereof | |
| KR20180018073A (en) | Livestock feed additives for substituting antibiotics and manufacturing method thereof | |
| JP2007332081A (en) | Health-and-cosmetic-functional composition, and food/drink and cosmetic each containing the same | |
| KR20210063657A (en) | A natural tea removing the effect of hangover contained the extract material in Hovenia dulcis and a cactus | |
| KR100768830B1 (en) | Extract of echinosophora koreensis removing hangover and having anti-oxidant activity | |
| KR101004361B1 (en) | The extracts and fractions of Hippophae rhamnoides L. | |
| KR102481102B1 (en) | Antibacterial composition containing starfish extract and cinnamon extract as active ingredients | |
| JP4376512B2 (en) | Angiotensin converting enzyme inhibitor and antihypertensive food | |
| KR102176983B1 (en) | Method of manufacturing cosmetic composition for acnes improvement and cosmetic composition for acnes improvement produced by the same | |
| CN106072668A (en) | Health product of eliminating toxin and beautifying the skin and preparation method thereof | |
| WO2006128335A1 (en) | Echinacea honey and its oral preparation | |
| KR101105367B1 (en) | Composition for Preventing Loss of Hair and Promoting Growth of Hair | |
| KR101655882B1 (en) | Composition for eliminating hangover comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| KR102390839B1 (en) | Staphylococcus-derived antibacterial substance mixture against Staphylococcus aureus and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |